title: High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma.
abstract: OBJECTIVE
  Involved field (IF) radiation can cure as many as 40% to 50% of patients with stage I-II low-grade lymphoma. We sought to improve these results by prospectively evaluating the combination of IF radiation and chemotherapy consisting of 10 courses of cyclophosphamide, vincristine, prednisone, and bleomycin, with doxorubicin added in a risk-adapted manner (COP/CHOP-Bleo).
  
  
  METHODS
  From 1984 until December 1992, 91 patients, median age 56 years (range 28 to 77 years), with clinical stage I-II low-grade lymphoma were treated. No patients were excluded on the basis of age or organ function.
  
  
  RESULTS
  A complete response was attained in 99% of evaluable patients. Treatment-related toxicity was mild, and no deaths occurred during therapy. With a median follow-up of 60 months, there have been only 16 relapses. The actuarial freedom from relapse rate at five years is 82% (95% confidence interval 71% to 89%) and at 10 years is 73%. At five years the overall survival rate is 90% (95% confidence interval 81% to 95%) and at ten years it is 82%. Of the clinical features examined, only older age (> 56 years; p = 0.07) was associated with shorter survival. No features examined were predictive of disease relapse.
  
  
  CONCLUSIONS
  The combination of IF radiation and risk-adapted COP/CHOP-Bleo chemotherapy is well-tolerated, produces a very high rate of complete remission, and with a median follow-up of five years, has produced lower rates of relapse and better overall survival than has been reported for IF radiation alone in patients with clinically-staged I-II low-grade lymphoma.
authors.affiliation: University of Texas, M.D. Anderson Cancer Center, Houston, USA.
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.forename: P
authors.initials: P
authors.lastname: McLaughlin
authors.forename: L M
authors.initials: LM
authors.lastname: Fuller
authors.forename: F B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: M
authors.initials: M
authors.lastname: Hess
authors.forename: F
authors.initials: F
authors.lastname: Swan
authors.forename: J
authors.initials: J
authors.lastname: Romaguera
authors.forename: M A
authors.initials: MA
authors.lastname: Rodriguez
authors.forename: P
authors.initials: P
authors.lastname: Besa
authors.forename: J
authors.initials: J
authors.lastname: Cox
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D012074:Remission Induction